Premium
Multimodality treatment of primary lymphoepithelioma‐like carcinoma of the lung
Author(s) -
Chan Anthony T. C.,
Teo Peter M. L.,
Lam Kwok C.,
Chan Wing Y.,
Chow John H. S.,
Yim Anthony P. C.,
Mok Tony S. K.,
Kwan Wing H.,
Leung Thomas W. T.,
Johnson Philip J.
Publication year - 1998
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19980901)83:5<925::aid-cncr18>3.0.co;2-x
Subject(s) - medicine , lymphoepithelioma like carcinoma , lymphoepithelioma , carcinoma , lung , dermatology , pathology , nasopharyngeal carcinoma , radiology , virology , radiation therapy , virus , epstein–barr virus
Abstract BACKGROUND Lymphoepithelioma‐like carcinoma (LELC) of the lung occurs at a higher frequency in Asian compared with Western patients. Its association with Epstein‐Barr virus varies among different ethnic groups. METHODS Nine patients with primary LELC of the lung treated at a single institution with a multimodality approach comprised of surgery, chemotherapy, and radiotherapy are reported. Chemotherapy was comprised of cisplatin, 100 mg/m 2 , on Day 1 and 5‐fluorouracil, 1 g/m 2 , on Days 2, 3, and 4. RESULTS Five male and 4 female patients were treated over a 3‐year period. Eight patients were non‐smokers. Three patients had operable disease. Two of these patients received adjuvant radiotherapy or chemotherapy and remained free of recurrence at 18 and 20 months, respectively; 1 patient received no adjuvant treatment, and palliative chemotherapy was given for subsequent recurrent disease. Six patients had inoperable disease and received palliative chemotherapy ± radiotherapy. Five patients had distant metastatic disease at presentation. Of the 7 patients who were evaluable for response to chemotherapy, 71.4% had a partial response and 28.6% had progressive disease. One patient who was evaluable for response to radiotherapy achieved a partial response. CONCLUSIONS Primary LELC of the lung has a high rate of systemic metastasis and is highly chemosensitive. A multimodality approach to the management of this disease is recommended. Cancer 1998;83:925‐929. © 1998 American Cancer Society.